A phase II dose-ranging study of mirabegron in patients with overactive bladder

Chapple, C.R. orcid.org/0000-0002-2960-9931, Dvorak, V., Radziszewski, P. et al. (9 more authors) (2013) A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal, 24 (9). pp. 1447-1458. ISSN 0937-3462

Abstract

Metadata

Authors/Creators:
  • Chapple, C.R. ORCID logo https://orcid.org/0000-0002-2960-9931
  • Dvorak, V.
  • Radziszewski, P.
  • Van Kerrebroeck, P.
  • Wyndaele, J.J.
  • Bosman, B.
  • Boerrigter, P.
  • Drogendijk, T.
  • Ridder, A.
  • Van der Putten-Slob, I.
  • Yamaguchi, O.
  • Grp, D.I.
Copyright, Publisher and Additional Information: © The Author(s) 2013. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Keywords: beta(3)-adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder
Dates:
  • Published: 8 March 2013
  • Accepted: 2 January 2013
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 02 May 2017 13:38
Last Modified: 02 May 2017 13:38
Published Version: http://doi.org/10.1007/s00192-013-2042-x
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s00192-013-2042-x
Related URLs:

Share / Export

Statistics